Table 2.
Clinical characteristics of study population
| Variable | Nonsurvivor group | Survivor group | p Value |
|---|---|---|---|
| (N = 20) | (N = 127) | ||
| Age (years) | 57 ± 11.74 | 50 ± 14.63 | .044 |
| Gender (male, n %) | 16 (80.0%) | 86 (67.7%) | .271 |
| WBC (×109/L) | 12.68 ± 5.79 | 9.28 ± 4.61 | .004 |
| Lym (×109/L) | 1.12 ± 0.93 | 1.36 ± 0.61 | .131 |
| Mo (×109/L) | 0.70 ± 0.34 | 0.55 ± 0.35 | .084 |
| Neu (×109/L) | 10.60 ± 5.66 | 7.25 ± 4.31 | .002 |
| HB (g/L) | 102.70 ± 13.75 | 106.62 ± 20.71 | .415 |
| PLT (×109/L) | 175.40 ± 105.34 | 202.01 ± 111.37 | .319 |
| ALT (U/L) | 22.7 (3.9−2433.3) | 24.1 (3.0−280.2) | .468 |
| AST (U/L) | 27.5 (13.7−3654.2) | 24.2 (9.1−218.6) | .360 |
| UREA (mmol/L) | 10.00 ± 6.23 | 6.45 ± 4.43 | .002 |
| CREA (mmol/L) | 83.8 (50.7−902.0) | 69.7 (37.1−944.2) | .028 |
| LWR | 0.10 ± 0.06 | 0.17 ± 0.08 | .001 |
| PLR | 200.61 ± 132.95 | 166.85 ± 106.52 | .205 |
| NLR | 9.33 (2.01−64.52) | 5.02 (0.05−72.53) | <.001 |
| SII | 1133.27 (374.47−9613.26) | 907.76 (141.79−10009.60) | .029 |
| SIRI | 5.21 (1.97−53.33) | 2.39 (0.04−56.34) | <.001 |
| Culture positive, n (%) | 8 (40.00%) | 43 (33.86%) | .593 |
| Culture negative, n (%) | 12 (60.00%) | 84 (66.14%) | .595 |
| Surgery (%) | 40.00% | 81.11% | <.001 |
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CREA, creatinine; HB, hemoglobin; Lym, lymphocyte; LWR = Lym/WBC; Mo, monocyte; Neu, neutrophil; NLR = Neu/Lym; PLT, platelet; PLR = PLT/Lym; SII = PLT × Neu/Lym; SIRI = Neu × Mo/Lym UREA, urea nitrogen; WBC, white blood cell.